We also performed ROC analysis of IGFBP2, IGFBP3, CA19-9, DUPAN-2 and Eq 1 in patients who would be considered at risk for pancreatic malignancy due to other diseases, such as mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), endocrine neoplasms, chronic pancreatitis and other conditions shown in Table 1 (all-stage set).We performed ROC analysis of these diseases against healthy controls and IDACP patients (Table 6). This evidence concerns the gene IGFBP3 and lipoid nephrosis.